博瑞医药BGM0504片获成人超重/肥胖患者临床试验批准

Core Viewpoint - The announcement from Borui Pharmaceutical indicates the approval of clinical trials for BGM0504 tablets, a dual agonist of GLP-1 and GIP receptors, aimed at treating overweight/obese adults [1] Group 1: Product Development - Borui Pharmaceutical's subsidiary, Borui Medicine, has received the clinical trial approval notice from the National Medical Products Administration for BGM0504 tablets [1] - BGM0504 is designed to have multiple biological effects, including blood sugar control, weight loss, and treatment of NASH [1] - The injectable form of BGM0504 has already entered Phase III clinical trials for type 2 diabetes and weight loss indications [1] Group 2: Market Position - Currently, there are no approved oral formulations targeting the same mechanism as BGM0504 globally [1] - The approval of BGM0504 tablets positions the company uniquely in the market for oral GLP-1 and GIP receptor agonists [1] Group 3: Investor Advisory - The company has advised investors to be aware of the long-term nature and uncertainties associated with drug development [1] - It is noted that the short-term impact on the company's operating performance will not be significant [1]